SOPHiA GENETICS $57.5 million follow-on offering
We advised SOPHiA GENETICS on the offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Rhône Capital acquisition of Invacare
We advised Highbridge Capital, as an Invacare secured lender and noteholder, on the transaction
Vistra $2.25 billion secured notes offering
We advised the underwriters on the offering
QXO $750 million follow-on offering
We advised the underwriter on the SEC-registered offering
Vistra $2 billion Cogentrix Energy bridge acquisition financing
We advised the lead arranger, lender and administrative agent on the financing
Immatics $125 million follow-on offering
We advised Immatics on the offering
ADC Therapeutics $60 million private placement
We advised ADC Therapeutics on the transaction involving its common shares and pre-funded warrants
Vistra $2 billion secured notes offering
The investment-grade notes are due 2028, 2030 and 2035
TopBuild $750 million notes offering
The high-yield notes are due 2034
K. Hovnanian Enterprises $900 million high-yield senior notes offering
The high-yield notes are due 2031 and 2033